Analyst Recommends Purchasing Johnson & Johnson Stock Before Earnings, Predicting Continued Growth.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy JNJ?
Source: Barron's
- Company Overview: One year ago, Johnson & Johnson was facing significant challenges due to the loss of exclusivity on a major product.
- Investor Concerns: The company struggled to reassure investors about its ability to generate revenue from other products to compensate for the loss.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 241.310
Low
190.00
Averages
218.50
High
240.00
Current: 241.310
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
S&P 500 Continues Upward Trend Amid Optimism
- Market Performance: The S&P 500 rose again on Friday, and a higher close would mark eight consecutive days of gains, primarily driven by the U.S.-Iran ceasefire news, although the Strait of Hormuz remains partially closed.
- Trading Strategy: Following a more than 18% rise in Broadcom last week, Jim Cramer plans to trim this position on Monday to protect profits and adjust the portfolio's size, adhering to a 72-hour trading rule for compliance.
- Earnings Season Outlook: Next week marks the start of earnings season, with Goldman Sachs set to report before the market opens on Monday, and Jim expects strong results due to market volatility; however, he is less optimistic about Wells Fargo and remains bullish on Johnson & Johnson.
- Rapid Fire Review: In Friday's rapid-fire segment, Jim covered stocks including CoreWeave, CarMax, and Lumentum, emphasizing that subscribers to the CNBC Investing Club will receive trade alerts before any transactions, ensuring transparency and compliance.
See More
Robust Clinical Data Supports TECNIS PureSee IOL Performance
- Clinical Study Results: The TECNIS PureSee IOL demonstrated exceptional distance and intermediate vision across two major studies in the U.S., Europe, and Asia-Pacific, with 91% of patients reporting minimal bothersome glare, 93% no halos, and 92% no starbursts, indicating significant advantages in visual quality.
- High Patient Satisfaction: A real-world observational study involving 293 patients revealed that 96% reported spectacle independence for distance, 95% for intermediate, and 61% for near vision, showcasing the success of TECNIS PureSee IOL in reducing reliance on glasses.
- Enhanced Visual Outcomes: In a U.S. prospective randomized clinical trial with 200 patients, TECNIS PureSee IOL provided high-quality distance vision and significantly improved intermediate vision compared to monofocal IOLs, with low levels of visual disturbances, further boosting surgical confidence.
- Commitment to Innovation: The data presented at the 2026 ASCRS Annual Meeting underscores Johnson & Johnson's commitment to innovation in vision health, aiming to advance technology through rigorous clinical research to enhance patient visual experiences.
See More
Johnson & Johnson: Strong Dividend Record and Diversified Business
- Dividend King Status: Johnson & Johnson (JNJ) boasts a remarkable 63-year streak of dividend increases, far surpassing the 54-year records of the other four healthcare Dividend Kings, showcasing its exceptional ability to provide stable income.
- Business Diversification: As one of the world's largest pharmaceutical companies, J&J not only holds a significant position in the drug sector but also benefits from its medical device business, which offers reliable cash flows that mitigate the risks associated with drug patent expirations.
- Future Plans: J&J plans to spin off its orthopedics business in 2027, focusing its medical device operations on cardiovascular, surgical, and vision sectors, which will further streamline its business and ensure continued revenue growth from its drug division.
- Credit Rating Advantage: With an AAA credit rating, J&J demonstrates solid financial health; although its dividend yield is around 2.2%, lower than the 4% target for many investors, its stability and reliability make it an attractive option in the pharmaceutical sector.
See More
Morgan Stanley and Citizens Financial Group Earnings Outlook
- Earnings Season Kickoff: The first-quarter earnings season begins next week with 28 companies in the S&P 500 set to report, and both Morgan Stanley and Citizens Financial Group are expected to exceed Wall Street's expectations, potentially driving their stock prices higher.
- Morgan Stanley Performance: Historically, Morgan Stanley has topped analysts' earnings estimates 80% of the time, with an average post-earnings gain of 1%, indicating strong market performance and investor confidence.
- Citizens Financial Group Outlook: Citizens Financial Group has also excelled in beating earnings expectations, achieving this 80% of the time, with an average stock price increase of 1.5% following earnings releases, reflecting its solid growth potential.
- Analyst Rating Upgrade: UBS upgraded Morgan Stanley's rating from neutral to buy, raising the price target to $196, implying an approximately 11% upside, which demonstrates market confidence in quality stocks amidst recent market volatility.
See More
Southern Co. Approaches Dividend Aristocrats Eligibility
- Dividend Aristocrats Eligibility: Southern Co. is nearing eligibility for the Dividend Aristocrats index, indicating its stability and reliability in consistent dividend payments, which attracts income-focused investors.
- Steady Earnings Growth: The company has achieved steady earnings growth, which is expected to enhance its market appeal, especially as demand for stable income rises in the current economic climate.
- Attractive Yield: With a current dividend yield of 3%, Southern Co. stands out in the low-interest-rate environment, potentially drawing more income-oriented investors looking for reliable returns.
- Potential Returns: As the company approaches Dividend Aristocrats status, it is anticipated to drive its stock price higher, providing substantial returns for investors and further solidifying its leadership position in the utility sector.
See More
Pharmaceutical Industry Automation Transformation Accelerates
- Regulatory Upgrades: The EU's updated GMP Annex 1 emphasizes minimizing human involvement and implementing comprehensive contamination control strategies, requiring manufacturers to assess and mitigate risks across personnel, processes, and environments, thus driving the pharmaceutical industry towards higher compliance standards.
- Intelligent Robotics Application: Nightfood Holdings is advancing AI-driven robotic platforms through TechForce Robotics, combining autonomous functionality with SOP intelligence and real-time deviation detection, aimed at enhancing compliance and operational efficiency in the pharmaceutical sector, reflecting the growing demand for intelligent systems in the industry.
- Persistent Contamination Risks: Despite technological advancements, FDA inspection findings indicate that deficiencies in contamination control and data integrity remain widespread, suggesting that traditional automation approaches have not fully addressed these issues, impacting drug supply chains and patient access to critical medications.
- Market Opportunities Emerge: The pharmaceutical manufacturing sector has been relatively slow to adopt automation, presenting significant market opportunities for technological advancement; Nightfood Holdings' strategic collaboration with Oncotelic Therapeutics aims to develop a GMP-compliant robotics platform, driving the industry's digital transformation.
See More
S&P 500 Continues Upward Trend Amid Optimism
- Market Performance: The S&P 500 rose again on Friday, and a higher close would mark eight consecutive days of gains, primarily driven by the U.S.-Iran ceasefire news, although the Strait of Hormuz remains partially closed.
- Trading Strategy: Following a more than 18% rise in Broadcom last week, Jim Cramer plans to trim this position on Monday to protect profits and adjust the portfolio's size, adhering to a 72-hour trading rule for compliance.
- Earnings Season Outlook: Next week marks the start of earnings season, with Goldman Sachs set to report before the market opens on Monday, and Jim expects strong results due to market volatility; however, he is less optimistic about Wells Fargo and remains bullish on Johnson & Johnson.
- Rapid Fire Review: In Friday's rapid-fire segment, Jim covered stocks including CoreWeave, CarMax, and Lumentum, emphasizing that subscribers to the CNBC Investing Club will receive trade alerts before any transactions, ensuring transparency and compliance.
See More
Robust Clinical Data Supports TECNIS PureSee IOL Performance
- Clinical Study Results: The TECNIS PureSee IOL demonstrated exceptional distance and intermediate vision across two major studies in the U.S., Europe, and Asia-Pacific, with 91% of patients reporting minimal bothersome glare, 93% no halos, and 92% no starbursts, indicating significant advantages in visual quality.
- High Patient Satisfaction: A real-world observational study involving 293 patients revealed that 96% reported spectacle independence for distance, 95% for intermediate, and 61% for near vision, showcasing the success of TECNIS PureSee IOL in reducing reliance on glasses.
- Enhanced Visual Outcomes: In a U.S. prospective randomized clinical trial with 200 patients, TECNIS PureSee IOL provided high-quality distance vision and significantly improved intermediate vision compared to monofocal IOLs, with low levels of visual disturbances, further boosting surgical confidence.
- Commitment to Innovation: The data presented at the 2026 ASCRS Annual Meeting underscores Johnson & Johnson's commitment to innovation in vision health, aiming to advance technology through rigorous clinical research to enhance patient visual experiences.
See More
Johnson & Johnson: Strong Dividend Record and Diversified Business
- Dividend King Status: Johnson & Johnson (JNJ) boasts a remarkable 63-year streak of dividend increases, far surpassing the 54-year records of the other four healthcare Dividend Kings, showcasing its exceptional ability to provide stable income.
- Business Diversification: As one of the world's largest pharmaceutical companies, J&J not only holds a significant position in the drug sector but also benefits from its medical device business, which offers reliable cash flows that mitigate the risks associated with drug patent expirations.
- Future Plans: J&J plans to spin off its orthopedics business in 2027, focusing its medical device operations on cardiovascular, surgical, and vision sectors, which will further streamline its business and ensure continued revenue growth from its drug division.
- Credit Rating Advantage: With an AAA credit rating, J&J demonstrates solid financial health; although its dividend yield is around 2.2%, lower than the 4% target for many investors, its stability and reliability make it an attractive option in the pharmaceutical sector.
See More
Morgan Stanley and Citizens Financial Group Earnings Outlook
- Earnings Season Kickoff: The first-quarter earnings season begins next week with 28 companies in the S&P 500 set to report, and both Morgan Stanley and Citizens Financial Group are expected to exceed Wall Street's expectations, potentially driving their stock prices higher.
- Morgan Stanley Performance: Historically, Morgan Stanley has topped analysts' earnings estimates 80% of the time, with an average post-earnings gain of 1%, indicating strong market performance and investor confidence.
- Citizens Financial Group Outlook: Citizens Financial Group has also excelled in beating earnings expectations, achieving this 80% of the time, with an average stock price increase of 1.5% following earnings releases, reflecting its solid growth potential.
- Analyst Rating Upgrade: UBS upgraded Morgan Stanley's rating from neutral to buy, raising the price target to $196, implying an approximately 11% upside, which demonstrates market confidence in quality stocks amidst recent market volatility.
See More
Southern Co. Approaches Dividend Aristocrats Eligibility
- Dividend Aristocrats Eligibility: Southern Co. is nearing eligibility for the Dividend Aristocrats index, indicating its stability and reliability in consistent dividend payments, which attracts income-focused investors.
- Steady Earnings Growth: The company has achieved steady earnings growth, which is expected to enhance its market appeal, especially as demand for stable income rises in the current economic climate.
- Attractive Yield: With a current dividend yield of 3%, Southern Co. stands out in the low-interest-rate environment, potentially drawing more income-oriented investors looking for reliable returns.
- Potential Returns: As the company approaches Dividend Aristocrats status, it is anticipated to drive its stock price higher, providing substantial returns for investors and further solidifying its leadership position in the utility sector.
See More
Pharmaceutical Industry Automation Transformation Accelerates
- Regulatory Upgrades: The EU's updated GMP Annex 1 emphasizes minimizing human involvement and implementing comprehensive contamination control strategies, requiring manufacturers to assess and mitigate risks across personnel, processes, and environments, thus driving the pharmaceutical industry towards higher compliance standards.
- Intelligent Robotics Application: Nightfood Holdings is advancing AI-driven robotic platforms through TechForce Robotics, combining autonomous functionality with SOP intelligence and real-time deviation detection, aimed at enhancing compliance and operational efficiency in the pharmaceutical sector, reflecting the growing demand for intelligent systems in the industry.
- Persistent Contamination Risks: Despite technological advancements, FDA inspection findings indicate that deficiencies in contamination control and data integrity remain widespread, suggesting that traditional automation approaches have not fully addressed these issues, impacting drug supply chains and patient access to critical medications.
- Market Opportunities Emerge: The pharmaceutical manufacturing sector has been relatively slow to adopt automation, presenting significant market opportunities for technological advancement; Nightfood Holdings' strategic collaboration with Oncotelic Therapeutics aims to develop a GMP-compliant robotics platform, driving the industry's digital transformation.
See More
